– Abidjan, July 24 (AIP) – A new drug, Tafenoquine, which will treat the recurrent or relapsing form of malaria, received the green light on Monday from the authorities of the Food and Drug Administration (FDA) in the United States. Indeed, the eradication of this type of malaria, caused by the plasmodium vivax, which makes 8.5 million people sick each year, remains a challenge for the scientific community. The reason is that it can remain dormant in the liver for years before making the subject sick several times. Children can be particularly at risk and have multiple malaria attacks just because of a single bite. It is a cause of absenteeism from school and weakens the patient each time when it …
Unless authorized by the editorial staff or a pre-established partnership, the resumption of AIP.CI articles, even partial, is strictly prohibited. Any offender is liable to prosecution.
Please log in to read the full text.
– .
